The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood
Introduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated.Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric M...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2010-05-01
|
| Series: | Güncel Pediatri |
| Subjects: | |
| Online Access: | http://www.guncelpediatri.com/yazilar.asp?yaziid=918&sayiid=25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846094821882593280 |
|---|---|
| author | Adem Parlak Aytuğ Dikililer Ümit Aydoğan Sebahattin Vurucu Bülent Ünay Rıdvan Akın |
| author_facet | Adem Parlak Aytuğ Dikililer Ümit Aydoğan Sebahattin Vurucu Bülent Ünay Rıdvan Akın |
| author_sort | Adem Parlak |
| collection | DOAJ |
| description | Introduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated.Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric Migraine Disability Assesment (PEDMİDAS) scores and grades of the patients were determined. Topiramate was given as 1 mg/kg/day then the dose was increased to 2 mg/kg/day at the tenth day of the treatment. At the third month, PEDMİDAS scores and grades were redetermined and compared with the first one.Results: The PEDMİDAS scores of the patients before and after the treatment were found as 34.60±22.28, 12.77±12.2, respectively. There was a statistical difference between these two values (p<0.001). When we group the patients according to the PEDMİDAS scores before the treatment 68% of the patients were grouped as grade 4, 23% as grade 3, 6% as grade 2 and 3% as grade 1; then after the treatment these percentages changed as 38.4% for grade 4, 29.4% for grade 3, 21.5% for grade 2 and 10.7% for grade1, respectively. Also forgetfulness in 8.8% (n=6) of patients, weight loss (average 250 grams) in 5.8% (n=4) and paresthesia in 4.4% (n=3) were determined.Conclusions: This study has shown that topiramate is safe, well tolerable and can be used with low doses in the treatment of chronic daily headache in childhood and is an alternative treatment choice that can be used in case no answers with other drugs. (Journal of Current Pediatrics 2010; 8: 20-3) |
| format | Article |
| id | doaj-art-f5d0614bc39d4471bd3d1e01b6f488b0 |
| institution | Kabale University |
| issn | 1304-9054 |
| language | English |
| publishDate | 2010-05-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Güncel Pediatri |
| spelling | doaj-art-f5d0614bc39d4471bd3d1e01b6f488b02025-01-02T12:14:06ZengGalenos Publishing HouseGüncel Pediatri1304-90542010-05-01812023The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in ChildhoodAdem ParlakAytuğ DikililerÜmit AydoğanSebahattin VurucuBülent ÜnayRıdvan AkınIntroduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated.Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric Migraine Disability Assesment (PEDMİDAS) scores and grades of the patients were determined. Topiramate was given as 1 mg/kg/day then the dose was increased to 2 mg/kg/day at the tenth day of the treatment. At the third month, PEDMİDAS scores and grades were redetermined and compared with the first one.Results: The PEDMİDAS scores of the patients before and after the treatment were found as 34.60±22.28, 12.77±12.2, respectively. There was a statistical difference between these two values (p<0.001). When we group the patients according to the PEDMİDAS scores before the treatment 68% of the patients were grouped as grade 4, 23% as grade 3, 6% as grade 2 and 3% as grade 1; then after the treatment these percentages changed as 38.4% for grade 4, 29.4% for grade 3, 21.5% for grade 2 and 10.7% for grade1, respectively. Also forgetfulness in 8.8% (n=6) of patients, weight loss (average 250 grams) in 5.8% (n=4) and paresthesia in 4.4% (n=3) were determined.Conclusions: This study has shown that topiramate is safe, well tolerable and can be used with low doses in the treatment of chronic daily headache in childhood and is an alternative treatment choice that can be used in case no answers with other drugs. (Journal of Current Pediatrics 2010; 8: 20-3)http://www.guncelpediatri.com/yazilar.asp?yaziid=918&sayiid=25Topiramateefficacyreliabilitychildhoodheadache |
| spellingShingle | Adem Parlak Aytuğ Dikililer Ümit Aydoğan Sebahattin Vurucu Bülent Ünay Rıdvan Akın The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood Güncel Pediatri Topiramate efficacy reliability childhood headache |
| title | The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood |
| title_full | The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood |
| title_fullStr | The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood |
| title_full_unstemmed | The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood |
| title_short | The Efficacy and Reliability of Topiramat Use in Chronic Daily Headache in Childhood |
| title_sort | efficacy and reliability of topiramat use in chronic daily headache in childhood |
| topic | Topiramate efficacy reliability childhood headache |
| url | http://www.guncelpediatri.com/yazilar.asp?yaziid=918&sayiid=25 |
| work_keys_str_mv | AT ademparlak theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT aytugdikililer theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT umitaydogan theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT sebahattinvurucu theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT bulentunay theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT rıdvanakın theefficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT ademparlak efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT aytugdikililer efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT umitaydogan efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT sebahattinvurucu efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT bulentunay efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood AT rıdvanakın efficacyandreliabilityoftopiramatuseinchronicdailyheadacheinchildhood |